MDMA-Assisted Therapy for PTSD
MAPS is currently sponsoring MAPP2, the second of two Phase 3 trials to support FDA approval of this breakthrough-designated therapy. In their first Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic